 |
 |
|||||
  |
 |
 |
 |
 |
 |
|
 |
|
FKH has been a key player in the lifescience and healthcare industries for more than 15 years. Our history is inexorably intertwined with that of the biotech sector and pharmaceutical PR. Feinstein Kean Healthcare was founded in 1987 to meet the unique communications needs of the emerging biotechnology industry. From the beginning, we realized the crucial role that strategic communications and investor relations programs played in building the value of companies not measured by traditional parameters. Marcia A. Kean, a leading figure in the biotechnology industry since the early 1980s, founded FKH's corporate communications practice in 1989. Under Marcia's leadership, the firm grew to serve the needs of more than 250 biotechnology companies, during the industry's multiple financing cycles. Over the years, we have added to our pharmaceutical practice a wide range of services and staff with experience in numerous therapeutic areas and successfully managing challenges and opportunities at every stage of the product life cycle. In 1999, FKH became part of Ogilvy Public Relations Worldwide, one of the nation's top ten agencies and a global leader in health, branding, marketing and public affairs. Yet we have chosen to remain a distinct entity, smaller and specialized, to help preserve the boutique qualities — depth of knowledge, personalized approach and great flexibility — that keep our clients coming back. Throughout, we've been an integral part of the communities we serve, nurturing close ties within the lifescience and healthcare industries and among those with whom we work: the media, academia, investors, Today, we remain exclusively focused on the healthcare and lifescience industries, offering our clients a depth of experience, breadth of expertise and network of affiliations that we believe no other agency can match. |
|
||
 |
||||
|
|
|
|
|